The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oklahoma Medical Research Foundation
• Collaborators: Arthritis and Rheumatic Disease Specialties; UCB Pharma
• Treatments: Certolizumab Pegol

Criteria

Inclusion Criteria:

• moderate to severe RA (DAS > 4.4)

• at least two swollen and tender joints in one of the hand/ wrist

• patients must have failed at least one non-biologic or biologic DMARDs

• currently receiving MTX therapy

Exclusion Criteria:

• concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment